Do you want lower cost medicines? Learn more about Biosimilars

Jun 4, 2019 | Actions, Featured Action, Federal Issues, Issues

There’s a scientific breakthrough happening right now for patients who are fighting diseases like cancer, colitis and rheumatoid arthritis. They are called Biosimilars. 

These new medicines are almost exact scientific copies of the drugs so many of us are all taking right now. Biosimilars represent the kind of innovation that patients are looking for every day. They are in ready supply and approved by the FDA.  

They are also 15-35%less than the drugs patients are taking right now. In fact, the independent RAND health research institute concluded that biosimilars could save $54 billion over 10 years. Last year alone, the FDA estimated biosimilars could have saved patients billions of dollars. 

But here’s the bad news: Some of health care’s most powerful special interests are trying to stop biosimilars. Insurance companies and the pharmacy benefit manager middlemen don’t want the competition. And the last thing they want is for patients to find out they can have the right medicine at a lower cost. 

The FDA has now approved 19 Biosimilar drugs, including for some of the most popular drugs in the country. But only seven are available to patients. In Europe, 54 Biosimilar drugs are on the market. 

If nothing is done to tear down the barriers to access, patients won’t be able to benefit from these new medicines. We can’t let that happen.

Sign Up to Learn More